Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial-Reference-Cited by-同舟云学术

Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Published:2016-10-27 Issue:2 Volume:102 Page:e47-e51
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Selleslag Dominik,Suciu Stefan,Meloni Giovanna,Muus Petra,Halkes Constantijn J.M.,Venditti Adriano,Ramadan Safaa M.,Pruijt Hans,Meert Liv,Vignetti Marco,Marie Jean-Pierre,Wittnebel Sébastian,de Witte Theo,Amadori Sergio,Willemze Roelof,Baron Frédéric

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation;Cancer Medicine;2020-03-18

2. Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission;Journal of Internal Medicine;2019-01-18

3. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials;Annals of Hematology;2018-06-20

4. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia;Pediatric Hematology and Oncology;2017-05-19

5. Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy;Expert Opinion on Biological Therapy;2016-12-21